Drug profile · INN
pegaptanib sodium
MACUGEN
pegaptanib sodium (MACUGEN) is a vascular endothelial growth factor a antagonist. Route of administration: intravitreal. Current US regulatory status: approved.
Drug details — pegaptanib sodium
- US status
- approved
- Class
- —
- Route
- INTRAVITREAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
pegaptanib sodium (MACUGEN) is a vascular endothelial growth factor a antagonist. Route of administration: intravitreal. Current US regulatory status: approved.
Key facts
Mechanism of action
Vascular endothelial growth factor A antagonist
Primary target: Vascular endothelial growth factor A, long form
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is pegaptanib sodium?
pegaptanib sodium (MACUGEN) is a vascular endothelial growth factor a antagonist. Route of administration: intravitreal. Current US regulatory status: approved.
What is the brand name for pegaptanib sodium?
MACUGEN is a marketed brand name for pegaptanib sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pegaptanib sodium?
pegaptanib sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.